Otsuka Signs a Development and Commercialization Agreement with Esperion for Nexletol (bempedoic acid) and Nexlizet (bempedoic acid and ezetimibe) in Japan

Shots:

• Esperion to receive $60M up front, $450M as development & commercial milestone and is eligible to receive 15-30% royalties in the sale of products in Japan. Otsuka will get exclusive rights to Nexletol and Nexlizet and will fund Japan-specific development costs associated with the products
• The collaboration leverages Esperion’s expertise in lipid management and Otsuka’s CV drug development and commercialization expertise in Japan
• The alliance will advance the commitment of both companies to provide cost-effective, oral, once-daily, non-statin LDL-C lowering therapies for patients with hypercholesterolemia in Japan

Click here ­to­ read full press release/ article | Ref: Business wire  | Image: Otsuka